Kornimate/medical-research-clean huggingface dataset:
application of 3d printing technique in small pulmonary nodule localization

Conditions: Lung Neoplasm; Thoracic Surgery, Video-Assisted

Summary: the trial is to evaluate the efficacy and safety of three-dimensional printed navigational template in the clinical application of small peripheral lung nodule localization.

localization of small lung nodule is challenging due to the difficulty of nodule recognition during vats. a three-dimensional printed navigational template was designed to aid percutaneous lung nodule localization, and its feasibility has been confirmed in previous study. the trial was conducted to confirm the non-inferiority of template-guided method to conventional ct-guided method in terms of localization accuracy.

Eligibility criteria:
inclusion criteria: 1. aged from 19 to 80 years 2. lesions located in peripheral lung tissue which can be removed by wedge resection 3. the maximum diameter of the lesion is no more than 20 mm. 4. research assistant consulted with the patient's surgeon to confirm the necessity of lung nodule localization 5. informed consent was signed voluntarily. exclusion criteria: 1. nodule located in the scapula region. 2. there were two or more lung nodules needed to be localized.

Keywords: printing, three-dimensional
aerobic endurance training vs. relaxation training in patients with migraine

Conditions: Migraine

Summary: this is a single centre, open label, prospective, randomized study on the prophylactic effect of moderate aerobic endurance training versus relaxation training in patients with migraine.


Eligibility criteria:
inclusion criteria: * patient's signature on the informed consent document \[each patient should be given ample time to read (or have read to them) the consent form, ask any questions they may have regarding the trial and have a clear understanding of the trial and the procedures involved prior to the signing of the consent form\]. * patients have a clinical diagnosis of migraine with or without aura according to ihs criteria at least one year prior to enrollment. * patients have a clinical diagnosis of migraine with or without aura and in addition a clinical diagnosis of tension type headache according to ihs criteria, if patients are able to differentiate between the two headache diagnoses and if migraine is more frequent in these patients * patients that report at least three headache days per month exclusion criteria: * diseases or disabilities that disqualify to perform either aerobic endurance training or relaxation training * language difficulties that disable to fill out questionnaires * pregnancy * additional diagnosis of secondary headache according to the ihs criteria
a study of pf-05175157 in healthy volunteers and type 2 diabetic patients

Conditions: Diabetes Mellitus, Type 2

Summary: the primary purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of pf-05175157 in healthy volunteers and patients with type 2 diabetes mellitus.


Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ecg and clinical laboratory tests. * in addition, subjects must have normal pulmonary function tests and normal ocular examination. * body mass index (bmi) of 25.5 - 35.5 kg/m2; and a total body weight \>50 kg (110 lbs). * women must be of non-childbearing potential. * subjects with type 2 diabetes: hba1c ≥7.0% and ≤10.0% if on metformin only, and ≥6.5% and ≤9.0% if patient requires to be washed-off an su or dpp-4i. * for subjects with type 2 diabetes, due to possible effects on disposition, cyp p450 3a4/5 and 2d6 substrates should not be co-administered with study medications. exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic seasonal allergies at time of dosing). * evidence or history of any chronic ongoing or current pulmonary disease. * history of smoking in the past 5 years and a history of smoking more than 10 pack years, or history or evidence of habitual use of other (non smoked) tobacco or nicotine containing products within 3 months of screening, or positive cotinine test at screening or day -3. * active ocular disease including infection, glaucoma, seasonal allergies, dry eye symptoms or retinal/optic nerve disease.

Keywords: phase 1 multiple doses safety pharmacokinetics pharmacodynamics healthy volunteers type 2 diabetic patients
computed tomography (ct) score and histopathology of the middle turbinate in chronic rhinosinusitis

Conditions: Chronic Rhinosinusitis

Summary: in a previous study (berger el al. old and new aspects of middle turbinate histopathology. otolaryngol head neck surg. 2009;140:48-54), the investigators reported significant histopathologic changes in the middle turbinate mucosa of patients with chronic rhinosinusitis compared with normal controls. however, patients' mean lund-mackay ct score was 6.5±6.7 and were considered as having a relatively limited sinus disease (a score of 1-8). nine to sixteen was considered as intermediate sinus disease, and 17-24 extensive. no osteomyelitic changes were seen in this study group. the investigators hypothesize that a comparison between the three groups of patients with chronic rhinosinusitis having limited, intermediate, and extensive sinus disease would show that the higher the ct staging, the greater the histopathologic changes of the middle turbinate. the investigators also expect to find osteomyelitic changes in the middle turbinate of patients with higher ct staging.


Eligibility criteria:
inclusion criteria: * adult patients with chronic rhinosinusitis who failed conservative medical treatment, * patients who stopped treatment (topical or systemic corticosteroids) at least two months before endoscopic sinus surgery. exclusion criteria: * immunosuppressed patients, * patients in whom no indication to excise the middle turbinate was found, and * patients in whom a pathologic evaluation of the middle turbinate was necessary (e.g., suspected neoplastic disorder).

Keywords: chronic rhinosinusitis computed tomography histology middle turbinate morphometry osteomyelitis polyps
"iontophoresis vs. phonophoresis" for treatment of subacromial impingement syndrome

Conditions: Subacromial Impingement Syndrome

Summary: the aim of this study was to compare the effects of iontophoresis and phonophoresis applications added to conventional treatment on pain, range of motion, disability, and functional status in the shoulder region in patients with subacromial impingement syndrome.

randomization: forty-seven patients were assessed, and 43 completed the study in this randomized trial. the participants were divided into two groups (iontophoresis:22 and phonophoresis:21) using the online randomization software (www.randomizer.org). all patients gave written informed consent after being verbally informed about the study. assessment period: assessments were conducted twice, at the start and after completion of the 10-session treatment program. session period: all treatment programs were delivered five days per week for two weeks. the total number of sessions was ten. analysis: the statistical analysis was performed using version 21 of the statistical package for the social sciences (spss).to verify normal distribution, the shapiro-wilk test and histogram curves were utilized. descriptive statistics for parametric variables included mean, standard deviation, and percentage. since the data exhibited normal distribution, independent sample t-tests were used for group comparison while paired sample t-tests were used to detect changes within the group. the significance level of p\<0.05 was deemed acceptable for all analyses. for variables with nominal assessments, data were analyzed utilizing yates continuity correction and fisher's exact chi-square test. the post hoc power of the study was calculated using gpower 3.1.9.1 software. the resting vas scores was taken as reference. in this context, cohen's effect size was calculated as 1.00. when the alpha error was accepted as 5%, and effect size was 1.00, the post hoc power was found to be 94.27%.

Eligibility criteria:
inclusion criteria: * patients diagnosed with stage i-ii sis * the ages between 18 and 65 years exclusion criteria: * having underwent shoulder surgery, * participated in a shoulder-related treatment program within the previous six months, * failed to adhere to the treatment program by 70% or more

Keywords: iontophoresis phonophoresis pain disability
optimalisation of therapeutic drug monitoring (tdm) of vancomycin in patients with central venous port devices

Conditions: Catheter-related Infection

Summary: recently, it was reported that when vancomycin levels are determined after port sampling, levels can be falsely increased potentially leading to wrong dose adjustments. the investigators conducted an in vitro experiment using several central venous port devices, in which different flushing techniques were evaluated yielding residual vancomycin levels of less than 0.5 mg/l. in this study, the investigators want to evaluate this flushing technique in vivo in 15 patients admitted with catheter-related infection and treated with systemic vancomycin and vancomycin antibiotic lock. the purpose is to assess if correct flushing can avoid spurious vancomycin levels obtained via port sampling.


Eligibility criteria:
inclusion criteria: * adult patients, * having central venous port device, * treated with systemic vancomycin in combination with vancomycin antibiotic lock exclusion criteria: * pregnant women, * children, * patients with 'do not resuscitate' (dnr) code

Keywords: vancomycin levels central venous port device peripherally obtained levels dose adjustments tdm
a comparative investigation of efficacy and complications in light and deep chemical peels

Conditions: Peeling Skin Syndrome

Summary: chemical peeling involves applying substances to the skin to induce controlled damage, which promotes the regeneration of fresh skin cells and enhances the skin's appearance.

this study will be a cross-sectional analysis with a sample size of 112 patients.

Eligibility criteria:
inclusion criteria: * healthy males and females aged 18-35 years. * willing to provide informed consent and follow the treatment protocol. exclusion criteria: * pregnant or breastfeeding women. * active skin conditions (e.g., acne, eczema). * use of medications that affect skin healing. * known allergies to chemical peel substances.
low laser therapy and hyaluronic acid as an adjunct to non-surgical periodontal therapy

Conditions: Periodontitis

Summary: periodontal disease is an oral disease characterized by microbially associated, host-mediated inflammation of the periodontium. in the treatment of periodontal disease, conventional periodontal therapy includes both surgical and non-surgical approaches. non-surgical therapy (i.e. scaling and root planing - srp) remains an essential part of periodontal therapy. here, diseased root surface debridement utilizing different hand and ultrasonic instrumentation is performed to facilitate periodontal re-attachment and to reduce the bacterial mass in the periodontal pocket. in the last decade, the use of lasers (light amplification by stimulated emission of radiation) has occupied part of the dialogue within periodontology due to several proposed advantages. in the arena of periodontology, laser use, as an adjunct to non-surgical therapy, was demonstrated to enhance periodontal healing; however, it is still the matter of debate. among laser applications, low-level laser therapy is recommended for its pain-reducing, woundhealing and anti-inflammatory effects. hyaluronic acid is a non-sulfated glycosaminoglycan and a major component of the extracellular matrix. it is found in various body fluids, such as gingival crevicular fluid, saliva, serum and synovial fluid. anti-inflammatory, anti-edematous and anti-bacterial activities of hyaluronic acid have been investigated in dentistry, specially in periodontology.

each participant will be assigned in one of three groups. in each group there will be 15 participants. different treatment protocols will be carried in each group as follows: group one (scaling and root planing), group two (scaling and root planing + laser), group three (scaling and root planing + hyaluronic acid). under local anesthesia we will perform scaling and root planing of the teeth in two sessions. the procedure be made with the use of ultrasonic (piezoled scaler, kavo, biberach, de) and hand instruments (gracey, hu friedy, chicago, il, usa). in group one, only scaling and root planning (srp) will be made. in group two, the use of a diode laser (dentsply sirona - sirolaser blue) will be added to the therapy. in group three, after the performance of srp, a gel containing hyaluronic acid (regedent, hyadent cross linked hyaluronic acid gel) will be applied intrasulcular.

Eligibility criteria:
inclusion criteria: * systemically healthy * nonsmokers * untreated periodontal disease (stage 3, grade b or c) * plaque index will not exceed 20% * at least 20 teeth in oral cavity exclusion criteria: * systemic diseases with impact on periodontal health * medication with impact on periodontal health * smokers * pregnant and lactating women * patients treated with antibiotics in the last 12 months * patients who had undergone periodontal treatment in the last year
diuretic effect evaluation of petroselinum crispum (parsley) in hypertensive patients

Conditions: Diurnal Enuresis; Hypertension

Summary: the use of alternative therapy, particularly herbal treatment is becoming prevalent among patients. many herbs are in-use for various ailments such as diabetes, digestive problems, fever, hepatitis and hypertension etc. the common belief is, herbs are safe and easy to access as compared to conventional therapy, however, most of the studies reported different side effects which may be toxic at times. these adverse effects are mostly due to incorrect use or lack of patient education. parsley is a plant with antioxidant, diuretic and antimicrobial properties. literature reported use of parsley as a diuretic by different communities in throughout the world. in vitro studies in animal have also reported the diuretic effect as well as proposed mechanisms for the use of parsley as diuretic however none of the studies have been conducted to investigate the diuretic effect of parsley in humans. this study aims to evaluate the diuretic and hence antihypertensive effect of parsley in hypertensive patients.

parsley botanically known as petroselinum crispum, belongs to the family umbeliferae, originated from mediterranean region however, it is cultivated almost throughout the world now-a-days. the plant has reported folkloric uses in different parts of the world; in iran the seeds of the plant is used for different pharmacological effects including antimicrobial, kidney stones, digestive disorders etc., in turkey the leaves of this plant is used to treat hypertension, diabetes and as a diuretic in morocco the leaves are used for arterial hypertension, diabetes, high blood pressure and cardiac diseases in spain the leaves of this plant are used to treat hypertension, diabetes, prostititis and anemia whereas in serbia the leaves of the plant are used to treat urinary tract diseases and infections. though the aforementioned literature supports the diuretic and anti-hypertensive potential of parsley however no in-vivo studies have been reported to establish its diuretic activity in human subjects. some studies have reported diuretic activity for seed aqueous extract in rats. still, to evaluate the effect in human subjects, an in-vivo phase-i clinical study is needed to support the pre-clinical in-vivo and in-vitro diuretic effects of this plant. our study aims to investigate the diuretic and anti-hypertensive activity of parsley in hypertensive individuals currently using conventional medication.

Eligibility criteria:
inclusion criteria: * any male or female patients with hypertension and already using conventional medications i.e. antihypertensive drugs. the consent forms will be provided to the patients and only those patients which are willing to participate will be included in the study. patients with more than 3 co-morbidities and at high-risk conditions will not be included in the study. exclusion criteria: * geriatric, pregnant and lactating patients will not be included in the study. more important, patients on diuretic medications as well as diabetes, will also be excluded from the study.
managing frailty through mobilization in males and female inpatients with cardiovascular disease

Conditions: Cardiovascular Diseases; Frailty

Summary: frailty describes the overall health of a person. inpatients with cardiovascular problems have a higher risk for frailty - or the sick are more likely to get sicker - causing longer hospital stays, hospital readmission, and death. females are particularly vulnerable to these problems, generally displaying higher frailty levels than males. in hospital, patients spend almost all their time in bed, and this lack of movement worsens cardiovascular and musculoskeletal health, sometimes lengthening patients' hospital stay and priming them for another cardiovascular event. prolonged sedentary time may be more detrimental on frailty among females than males. the proposed pilot project will test if an in-hospital general medicine mobilization program reduces frailty (measure of overall health) in male and female inpatients with cardiovascular disease. a kinesiologist will provide daily check-ins and promote daily movement (e.g., standing more, resistance bands, physical activity promotion, etc.). the investigators expect both males and females will lower their frailty levels, but given their higher frailty levels in general and because females are typically less active than males, the investigators expect the intervention's effects to be greatest among females. sixty patients (30 females) will be recruited. patients with a major heart problem, projected to be in-hospital for at least 3-days, and can independently provide consent. frailty will be measured using a validated questionnaire. participants will also be equipped with activity monitors for 24h/d continuous wear to measure amount of time spent stepping, sitting, and lying. hospital records will be used for length of stay and readmissions. the investigators will compare the outcomes (activity and frailty) between males and females to determine if the intervention impacted each sex differently. this work will guide improved care plans to decrease frailty and improve health outcomes in both male and female patients with heart problems.


Eligibility criteria:
inclusion criteria: * patients who are admitted to unit 4c at the vitalité health network * patients who have a cardiovascular disease (e.g., heart failure) * those who are projected to be in-hospital for at least 3-days * patients who are not in a shared room with another study participant * patients who are able to independently provide consent or have a caregiver provide consent * can communication in french or english exclusion criteria: -patients enrolled in other clinical trials or interventions that might confound the results of the study.

Keywords: frailty management mobilization sex differences physical activity cardiovascular disease
a study to assess the long-term safety and efficacy of erenumab (amg 334) in chronic migraine prevention.

Conditions: Treatment for Prevention of Chronic Migraine

Summary: to assess the long-term safety and efficacy of erenumab.

this was a multicenter, 52-week, open-label study designed to assess the long-term safety and efficacy of erenumab in adults with chronic migraine. participants who completed the 12-week double-blind treatment of the parent study 20120295 (nct02066415) and met all study 20130255 eligibility criteria were eligible for enrollment into this study. enrollment occurred within 14 days after the parent study's week 12 visit. the initial dose used in the study was erenumab 70 mg every month (qm). the protocol was subsequently amended to increase the dose to erenumab 140 mg qm (protocol amendment 2). participants who had already completed the week 28 visit (ie, midpoint of the study) at the time of protocol amendment 2 continued to receive open-label erenumab 70 mg qm for the remainder of the study. participants who enrolled but had not completed the week 28 visit at the time of protocol amendment 2 increased the open-label erenumab dose from 70 mg qm to 140 mg qm at the next visit. all participants who enrolled after protocol amendment 2 received open-label erenumab 140 mg qm throughout the study. participants may elect to participate in a separate clinical home use (chu) substudy to assess subjects' ability to self-administer 140 mg of erenumab for in-home use using either two prefilled syringes (pfs) or two prefilled autoinjector/pens (ai/pens). enrollment in the 12-week substudy occurred at either week 12 or week 40 of study 20130255. participants were randomized to self-administer erenumab using either the pfs or ai/pen on chu days 29 and 57 at home.

Eligibility criteria:
inclusion criteria: 1. subject has provided informed consent prior to initiation of any study-specific activities/procedures 2. completed the 12-week study visit and did not end ip early during the double-blind treatment period of the amg 334 20120295 (nct02066415) parent study, and is appropriate for continued treatment. exclusion criteria: 1. development of any unstable or clinically significant medical condition, laboratory or electrocardiogram (ecg) abnormality following randomization into the parent study, that in the opinion of the investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion. 2. systolic blood pressure (bp) 160 mm hg and/or diastolic bp 100 mm hg or greater at screening/day 1. 3. subject who used excluded concomitant medications between week 8 and week 12 of the parent study

Keywords: chronic migraine
integrated neuromuscular inhibition technique and myofascial release on cervical range of motion and dysfunction

Conditions: Myofascial Trigger Point Pain

Summary: to findout the improvement by integrated neuromuscular inhibition technique and myofascial release on cervical range of motion and dysfunction


Eligibility criteria:
inclusion criteria: * ● age between 25-40 * both males and females included * participants suffering from recent cervical pain without any pathology. exclusion criteria: * ● participants having cervical radiculopathy * having recent trauma of the cervical spine * non-cooperative subject